A B S T R A C T The cardiovascular responses elicited by dobutamine are distinctly different from those produced by other adrenergic or dopaminergic agonists. To test the hypothesis that dobutamine could have differential affinities for adrenergic receptor subtypes, and that such subtype selectivity could be related to its relatively unique pharmacologic properties, we assessed the ability of dobutamine to displace adrenergic radioligands from membrane receptors in a number of tissues of previously characterized adrenergic receptor subtype. For beta adrenergic receptors identified by (-) [3H]dihydroalprenolol (DHA), dobutamine had significantly greater affinity for the ,f3 subtype (KD = 2.5 MM in rat heart and 2.6 MM in turkey erythrocyte) than for the (82 subtype (KD = 14.8 AM in frog heart and 25.4 ,uM in rat lung) (P < 0.001). For alpha adrenergic receptors, dobutamine had markedly greater affinity for the a,-subtype identified by [3H]prazosin (KD = 0.09 ,uM in rat heart and 0.14 AM in rabbit uterus) than for the a2-subtype identified by [3H]dihydroergocryptine (DHE) (KD = 9.3 MuM in human platelet) or by [3H]-yohimbine (KD = 5.7 MM in rabbit uterus) (P < 0.001).Like other 3B,-agonists, in the absence of guanine nucleotide, dobutamine competition curves for DHA binding in rat heart demonstrated two classes of binding sites, with one site of significantly higher affinity (KD = 0.5 MM, P = 0.008) than the single class of binding sites (KD = 5.2 MuM) identified in the presence of guanine nucleotide. However, unlike /32-or a2-agonists, dobutamine displacement of DHA binding in rat lung or of DHE binding in human platelets demonstrated only a single class of binding sites, and guanine nucleotide had only minimal effects.